Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

A Novel YAP/TAZ Inhibitor with a Unique Mechanism: Targeting Nuclear Transport

EF 2025-26

Résumé
YAP and TAZ are proteins that regulate cell growth, tissue repair, and cell survival. When these proteins become overactive, they can drive excessive tissue scarring and contribute to cancer progression. Normally, YAP/TAZ activity is suppressed by the Hippo pathway, which prevents them from entering the nucleus where they activate genes that promote cell growth and survival. However, how these proteins move between the nucleus and cytoplasm independently of Hippo remains poorly understood. Our lab recently identified unique sequences in YAP/TAZ that control their movement in and out of the nucleus. We are investigating VT00869 (VT), a newly discovered compound that suppresses YAP/TAZ activity through a previously unknown, Hippo-independent mechanism. So far, our experiments indicate that VT promotes the export of YAP/TAZ from the nucleus and increases levels of exportin-1 (XPO1), a protein responsible for transporting many molecules out of the nucleus. Unlike existing drugs that inhibit XPO1, VT appears to selectively enhance the export of YAP/TAZ while leaving other essential nuclear proteins, such as tumor suppressors, unaffected. My project will build on our previous work and determine whether VT modulates YAP/TAZ activity through XPO1, and whether this selectively reduces their gene-activating function. By comparing VT with established nuclear export inhibitors, I aim to define a novel, selective mechanism to suppress harmful YAP/TAZ activity while maintaining the function of protective nuclear proteins. Ultimately, understanding how YAP and TAZ move between the nucleus and cytoplasm could uncover new strategies to prevent their pathological overactivation and target disease-driving pathways in cancer and fibrosis, enabling a more precise therapeutic approach.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
573045
Name
Parekh Kinjal V
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A Novel YAP/TAZ Inhibitor with a Unique Mechanism: Targeting Nuclear Transport
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Hippo Pathway; Nuclear Export; Nuclear-Cytoplasmic Transport; Protein Stability; Proximity Ligation Assay; Qrt-Pcr; Small Molecule Inhibitor (Vt00869); Transcriptional Regulation; Western Blot; Yap/Taz
Abstract
YAP and TAZ are proteins that regulate cell growth, tissue repair, and cell survival. When these proteins become overactive, they can drive excessive tissue scarring and contribute to cancer progression. Normally, YAP/TAZ activity is suppressed by the Hippo pathway, which prevents them from entering the nucleus where they activate genes that promote cell growth and survival. However, how these proteins move between the nucleus and cytoplasm independently of Hippo remains poorly understood. Our lab recently identified unique sequences in YAP/TAZ that control their movement in and out of the nucleus. We are investigating VT00869 (VT), a newly discovered compound that suppresses YAP/TAZ activity through a previously unknown, Hippo-independent mechanism. So far, our experiments indicate that VT promotes the export of YAP/TAZ from the nucleus and increases levels of exportin-1 (XPO1), a protein responsible for transporting many molecules out of the nucleus. Unlike existing drugs that inhibit XPO1, VT appears to selectively enhance the export of YAP/TAZ while leaving other essential nuclear proteins, such as tumor suppressors, unaffected. My project will build on our previous work and determine whether VT modulates YAP/TAZ activity through XPO1, and whether this selectively reduces their gene-activating function. By comparing VT with established nuclear export inhibitors, I aim to define a novel, selective mechanism to suppress harmful YAP/TAZ activity while maintaining the function of protective nuclear proteins. Ultimately, understanding how YAP and TAZ move between the nucleus and cytoplasm could uncover new strategies to prevent their pathological overactivation and target disease-driving pathways in cancer and fibrosis, enabling a more precise therapeutic approach.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Parekh, Kinjal V
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~